Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

Abstract Background Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovas...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lynne Chepulis, Mark Rodrigues, Han Gan, Rawiri Keenan, Tim Kenealy, Rinki Murphy, Leanne Te Karu, Jo Scott-Jones, Penny Clark, Allan Moffitt, Sara Mustafa, Ross Lawrenson, Ryan Paul
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-03-01
Edice:	BMC Health Services Research
Témata:	SGLT2i GLP1RA Type 2 diabetes Health system access
On-line přístup:	https://doi.org/10.1186/s12913-025-12601-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!